echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Japan's Ministry of Health, Labour and Welfare approves CAR-T cell therapy Breyanzi for the treatment of DLBCL and follicular lymphoma

    Japan's Ministry of Health, Labour and Welfare approves CAR-T cell therapy Breyanzi for the treatment of DLBCL and follicular lymphoma

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Large B-cell lymphoma includes several disease types, including diffuse large B-cell lymphoma (DLBCL).


    Lymphoma

    Bristol-Myers Squibb recently announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Breyanzi (lisocabtagene maraleucel, liso-cel), a chimeric antigen receptor (CAR) T cell therapy targeting CD19 for the treatment of relapse Or refractory patients (R/R) large B-cell lymphoma and R/R follicular lymphoma.


    The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Breyanzi (lisocabtagene maraleucel, liso-cel), a chimeric antigen receptor (CAR) T cell therapy targeting CD19 for the treatment of relapsed or refractory patients (R /R) Large B-cell lymphoma and R/R follicular lymphoma.


    The approval is based on the efficacy and safety data of the TRANSCEND NHL 001 trial in R/RB cell non-Hodgkin’s lymphoma (NHL) patients, and the effectiveness and safety of the TRANSCEND WORLD trial in R/R follicular lymphoma patients Sexual data.


    Jean-Christophe Barland, President and CEO of Bristol-Myers Squibb, said: "I am very pleased that we have received Breyanzi's regulatory approval in Japan, which will allow us to treat relapsed or refractory large B-cell lymphoma and follicular lymphoma.


     

    Original source:

    Original source:

    href="" target="_blank" rel="noopener">leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.